acute leukemia, myelodysplastic syndrome, chronic myelogenous leukemia
Conditions
Interventions
Allogeneic hematopoietic stem cell transplantation with plerixafor-combined myeloablative conditioning
Sponsors
Division of Hematology Keio University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Acute myeloid or lymphoblastic leukemia not in remission or with high-risk cytogenetics 2) Chronic myelogenous leukemia in accelerated phase, blastic crisis, and second chronic phase 3) myelodysplastic syndrome with 10% or greater blast in bone marrow or 5% or greater in peripheral blood
Exclusion criteria
Exclusion criteria: Moderate or severe dysfunction in major organs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events within 28 days after transplantation | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) neutrophil engraftment 2) red cell and platelet engraftment 3) non-relapse mortality with 28 days after transplantation 4) 1-year overall and non-relapse survivial 5) 1-year relapse rate 6) acute and chronic GVHD 7) Infectous complications | — |
Countries
Japan
Contacts
Public ContactTakehiko Mori
Keio University School of Medicine Division of Hematology
Outcome results
None listed